Pathologic-Based Nomograms for Predicting Overall Survival and Disease-Free Survival Among Patients with Locally Advanced Rectal Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang X, Shi Y, et al. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin Cancer Res. 2017;23(23):7253–7262. doi:10.1158/1078-0432.CCR-17-103828939744
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Gosens MJEM, Marijnen CAM, Rutten HJ, van de Velde CJH, van Krieken JHJM. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. J Clin Oncol. 2007;25(13):1647–1650. doi:10.1200/JCO.2005.05.482517470856
   PubMed Web of Science ®Google Scholar
• Delitto D, George TJ, Loftus TJ, et al. Prognostic value of clinical vs pathologic stage in rectal cancer patients receiving neoadjuvant therapy. J Natl Cancer Inst. 2018;110(5):460–466. doi:10.1093/jnci/djx22829165692
   PubMedGoogle Scholar
• Valentini V, van Stiphout RGPM, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163–3172. doi:10.1200/jco.2010.33.159521747092
   PubMed Web of Science ®Google Scholar
• Li Z, Xie P, Zhang D, et al. Nomogram for predicting disease-free survival among a multicenter cohort of Chinese patients with locally advanced rectal cancer. Cancer Manag Res. 2019;11:2471–2483. doi:10.2147/CMAR.S19661431114319
   PubMed Web of Science ®Google Scholar
• Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796–804. doi:10.1016/j.eururo.2018.08.03830241973
   PubMed Web of Science ®Google Scholar
• Meyer JE, Cohen SJ, Ruth KJ, Sigurdson ER, Hall MJ. Young age increases risk of lymph node positivity in early-stage rectal cancer. J Natl Cancer Inst. 2015;108(1):djv284. doi:10.1093/jnci/djv284
   Google Scholar
• Ngeow J, Eng C. Rectal cancer: age matters in the affairs of stage. J Natl Cancer Inst. 2016;108(1):djv325. doi:10.1093/jnci/djv325
   Google Scholar
• Hofheinz RD, Arnold D, Fokas E, et al. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 Phase III trial. Ann Oncol. 2018;29(8):1793–1799. doi:10.1093/annonc/mdy20529873684
   PubMed Web of Science ®Google Scholar
• Sarasqueta C, Zunzunegui MV, Enríquez Navascues JM, et al. Gender differences in stage at diagnosis and preoperative radiotherapy in patients with rectal cancer. Bmc Cancer. 2020;20(1). doi:10.1186/s12885-020-07195-4
   Web of Science ®Google Scholar
• Diefenhardt M, Ludmir EB, Hofheinz RD, et al. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 randomized clinical trials of rectal cancer. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.5102
   Web of Science ®Google Scholar
• Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from intergroup trial 0114. J Clin Oncol. 2004;22(4):648–657. doi:10.1200/JCO.2004.07.12114966087
   PubMed Web of Science ®Google Scholar
• Taylor FGM, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone. Ann Surg. 2011;253(4):711–719. doi:10.1097/SLA.0b013e31820b8d5221475011
   PubMed Web of Science ®Google Scholar
• Kennedy ED, Simunovic M, Jhaveri K, et al. Safety and feasibility of using magnetic resonance imaging criteria to identify patients with “good prognosis” rectal cancer eligible for primary surgery. JAMA Oncol. 2019;5(7):961. doi:10.1001/jamaoncol.2019.018630973610
   PubMed Web of Science ®Google Scholar
• Bozzetti F. The site of the tumor, not the type of operation, determines the worse prognosis of the low rectal cancer. Ann Surg. 2006;244(2):330–331. doi:10.1097/01.sla.0000230007.89561.9116858206
   PubMed Web of Science ®Google Scholar
• Sunil PV, Roxburgh CS, Vakiani E, et al. Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. J Surg Oncol. 2016;114(5):637–641. doi:10.1002/jso.2435827641934
   PubMed Web of Science ®Google Scholar
• Restivo A, Zorcolo L, Cocco IMF, et al. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol. 2013;20(3):864–871. doi:10.1245/s10434-012-2669-823010737
   PubMed Web of Science ®Google Scholar
• Hu H, Huang J, Lan P, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial. Bmc Cancer. 2018;18(1). doi:10.1186/s12885-018-4997-y
   Web of Science ®Google Scholar
• Fokas E, Allgauer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212–3222. doi:10.1200/JCO.19.0030831150315
   PubMedGoogle Scholar
• Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37(34):3223–3233. doi:10.1200/JCO.18.0230931557064
   PubMed Web of Science ®Google Scholar
• Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12(4):513–519. doi:10.6004/jnccn.2014.005624717570
   PubMed Web of Science ®Google Scholar
• Abdalla A, Aref A. Upfront chemotherapy followed by chemoradiation remains the sequence of choice for total neoadjuvant chemotherapy for locally advanced rectal cancer. J Clin Oncol. 2019;37(36):3561–3562. doi:10.1200/JCO.19.0172231596633
   PubMed Web of Science ®Google Scholar
• Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31):3773–3780. doi:10.1200/JCO.2016.67.604927432930
   PubMed Web of Science ®Google Scholar
• Li J, Li J. Can a longer waiting period after neoadjuvant chemoradiotherapy improve the pathologic complete response rate in patients with rectal cancer? J Clin Oncol. 2017;35(15):1747–1748. doi:10.1200/JCO.2016.69.731828524777
   PubMedGoogle Scholar
• Jeong S, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767–774. doi:10.1016/S1470-2045(14)70205-024837215
   PubMed Web of Science ®Google Scholar
• Fleshman J, Branda ME, Sargent DJ, et al. Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer. Ann Surg. 2019;269(4):589–595. doi:10.1097/SLA.000000000000300230080730
   PubMed Web of Science ®Google Scholar
• Swets M, Kuppen PJK, Blok EJ, Gelderblom H, van de Velde CJH, Nagtegaal ID. Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy? Eur J Cancer. 2018;89:1–8. doi:10.1016/j.ejca.2017.11.00629223019
   PubMed Web of Science ®Google Scholar
• Karagkounis G, Thai L, Mace AG, et al. Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage III rectal cancer. Ann Surg. 2019;269(6):1117–1123. doi:10.1097/SLA.000000000000271931082910
   PubMed Web of Science ®Google Scholar
• Bregni G, Akin TT, Camera S, et al. Adjuvant chemotherapy for rectal cancer: current evidence and recommendations for clinical practice. Cancer Treat Rev. 2020;83:101948. doi:10.1016/j.ctrv.2019.10194831955069
   PubMed Web of Science ®Google Scholar
• Spiegel DY, Boyer MJ, Hong JC, et al. Survival advantage with adjuvant chemotherapy for locoregionally advanced rectal cancer: a veterans health administration analysis. J Natl Compr Canc Netw. 2020;18(1):52–58. doi:10.6004/jnccn.2019.732931910388
   PubMed Web of Science ®Google Scholar
• Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30(15):1770–1776. doi:10.1200/jco.2011.39.790122493423
   PubMed Web of Science ®Google Scholar
• Borschitz T, Wachtlin D, Mohler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol. 2008;15(3):712–720. doi:10.1245/s10434-007-9732-x18163173
   PubMed Web of Science ®Google Scholar
• Yang H, Yao Z, Cui M, et al. Influence of tumor location on short- and long-term outcomes after laparoscopic surgery for rectal cancer: a propensity score matched cohort study. Bmc Cancer. 2020;20(1):761. doi:10.1186/s12885-020-07255-932795280
   PubMed Web of Science ®Google Scholar
• Frambach P, Pucciarelli S, Perin A, et al. Metastatic pattern and new primary tumours after neoadjuvant therapy and surgery in rectal cancer. Colorectal Dis. 2018;20(12):O326–O334. doi:10.1111/codi.1442730230157
   PubMed Web of Science ®Google Scholar
• Huang Q, Qin H, Xiao J, et al. Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy. Gastroenterol Rep. 2019;7(4):283–290. doi:10.1093/gastro/goy045
   Google Scholar
• Jögi A, Vaapil M, Johansson M, Påhlman S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Uppsala J Med Sci. 2012;117(2):217–224. doi:10.3109/03009734.2012.659294
   PubMed Web of Science ®Google Scholar
• Qiu HZ, Wu B, Xiao Y, Lin GL. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. Colorectal Dis. 2011;13(12):1353–1360. doi:10.1111/j.1463-1318.2011.02570.x21689282
   PubMed Web of Science ®Google Scholar
• Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–190. doi:10.1016/S1470-2045(13)70599-024440473
   PubMed Web of Science ®Google Scholar
• Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–207. doi:10.1016/S1470-2045(14)71199-425589192
   PubMed Web of Science ®Google Scholar